· FDA granted Fast Track Designation for 2L Acute Myeloid Leukaemia (AML)
  · High Impact oral presentation of 2L NSCLC clinical data at SITC
  · Met primary and secondary endpoints in non-small cell lung cancer (NSCLC)
Phase II clinical trial in patients previously treated with chemotherapy (cohort
A)
  · Proprietary composite AXL tumor immune score (cAXL) identified patients that
have shown very durable response and significantly prolonged median Progression
Free Survival (mPFS)
  · Proprietary gene signature identified 2L NSCLC patients that had durable
benefit and was independent of PD-L1
  · Phase Ib/II interim safety data with bemcentinib in combination with
pembrolizumab or BRAF/MEK inhibitors in 1L Melanoma confirmed the combinations
are well tolerated by patients
  · Cash and Cash equivalents at end of Q3 2019 NOK 289.5 million (NOK 398.2
million in Q3 2018)
  · Operating loss of NOK 47.5 million in Q3 2019 (NOK 38.1 million in Q3 2018)
and NOK 145.3 million YTD 2019 (NOK 143.6 million YTD 2018)

Bergen, Norway, 19 November 2019 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
multiple cancer indications, announces its results for the third quarter 2019.

A presentation and live webcast by the Company's management will take place
today at 10.00 am CET in Oslo, please see below for details.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: "During the
quarter we have continued working to expand our proof of concept trials in AML
and NSCLC. Our goal is to confirm that the addition of our selective AXL
inhibitor bemcentinib can substantially improve patient outcomes across both
these indications. This will inform clinical strategy and position for late
stage clinical development, and we remain committed to progressing bemcentinib
through to regulatory approval."

Operational Highlights - Third quarter 2019

Non-Small Cell Lung Cancer (NSCLC)

  · Cohort A of the Phase II clinical trial (BGBC008) evaluating bemcentinib in
combination with KEYTRUDA in patients with NSCLC met its primary endpoint.
    · Primary endpoint of Overall Response Rate (ORR) was met, with 33% ORR in
cAXL positive patients; five times the response rate of cAXL negative patients
(7%)
    · Response rate three times greater than that seen with Keytruda monotherapy
reported in earlier clinical trials in similar patients.
    · Secondary endpoint of median Progression Free Survival (mPFS) reported
significant 3-fold improvement in cAXL positive vs negative patients,
    · Data were presented at the prestigious High Impact Clinical Trial session
at the Society for Immunotherapy of Cancer (6-10 November 2019) conference in
Washington DC.

  · Proprietary Composite AXL Immune Score (cAXL) suggests patients that express
AXL in both their tumor and immune cells report significantly improved clinical
benefit from bemcentib combination with Keytruda.

  · Data from Cohort A of BGBC008 was also presented in an oral presentation at
the 2019 World Conference on Lung Cancer (WCLC) and as a poster the European
Society of Medical Oncology Congress (ESMO).

  · Data suggest bemcentinib has potential to enhance patient responses and
overall survival, when treated in combination with a PD-1 inhibitor,
particularly in patients with no or limited expression of PD-L1, this is a very
significant patient population, and a very encouraging development.

  · The clinical trial BGBC008 is ongoing in two additional cohorts; B) in Check
Point Inhibitor refractory patients and C) in CPI/chemotherapy combination
refractory patients. Preliminary data read out is anticipated in the first half
of 2020.

Acute Myeloid Leukaemia (AML)

  · U.S Food and Drug Administration (FDA) has granted bemcentinib Fast Track
Designation for the treatment of elderly patients with AML whose disease has
relapsed.
    · The purpose of the Fast Track designation is to get important new drugs to
the patients earlier
    · The Fast Track program is designed to facilitate the development and
expedite the regulatory review of new drugs to treat serious conditions without
any treatment options.

  · Phase IIa clinical trial data has shown that bemcentinib in combination with
low-intensity chemotherapy (LDAC) in elderly AML patients is well tolerated and
efficacious.
    · Preliminary responses were reported in 43% of evaluated patients, with
complete responses in a substantially higher percentage of patients compared to
previously observed/historical benchmarks in single-agent cytarabine.
    · Trial has been expanded to include an additional 28 patients to verify
this early proof of concept, preliminary data from this expanded trial will be
reported in the first half of 2020.

  · Cash and Cash equivalents at end of Q3 2019 NOK 289.5 million (NOK 398.2 in
Q3 2018).



Financial highlights

·      Revenue for the third quarter 2019 and the nine months ended 30 September
2019 respectively amounted to NOK 0 million (NOK 0 million) and NOK 8.7 million
(NOK 0 million). The revenue was received in Q1 2019 from ADCT as a clinical
milestone payment.

·     Total operating expenses for the third quarter and the nine months ended
30 September 2019 respectively amounted to NOK 47.5 million (NOK 38.1 million)
and NOK 154.0 million (NOK 143.6 million).

  ·
Cash and Cash equivalents at end of Q3 2019 NOK 289.5 million (NOK 398.2 in Q3
2018)



Presentation and Webcast Details

A presentation by BerGenBio's senior management team will take place today at
10:00 am CET at:

Arctic Securities

Haakon VIIs gate 5

Oslo

The presentation will webcast live and the link will be available
at www.bergenbio.com in the section Investors/Financial Reports. A recording
will be available shortly after the webcast has finished.

The results report and presentation will be available at www.bergenbio.com in
the section: Investors/Financial Reports from 7:00 am CET.

-END-

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, drug resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad Phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer and
leukaemia. A first-in-class functional blocking anti-AXL antibody is undergoing
Phase I clinical testing. In parallel, BerGenBio is developing a companion
diagnostic test to identify those patient populations most likely to benefit
from bemcentinib: this is expected to facilitate more efficient registration
trials supporting a precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Nicholas Brown, Carina Jurs &
Taiana De Ruyck Soares, Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.